Probi Stock

Probi EV/EBIT

Delisted

The EV/EBIT (Enterprise Value to EBIT) of Probi (PROB.ST) as of Jul 23, 2026 is 350.28. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 78.40 — a change of 346.77% (higher).

EV/EBIT

350.28

YoY

346.77%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Probi is 2026 350.28 . EV/EBIT (Enterprise Value to EBIT) of Probi was 2025 78.40 . It decreases by 346.77% higher compared to the previous year.

The Probi EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
0.00 base
Jan 1, 2020
0.00 base
Jan 1, 2021
0.00 base
Jan 1, 2022
0.00 base
Jan 1, 2023
0.00 base
Jan 1, 2024 (e)
0.00 base
Jan 1, 2025 (e)
0.00 base
Jan 1, 2026 (e)
0.00 base
YEARPRICE-TO-EBIT
2026 est -
2025 est -
2024 est -
2023 -
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
2010 -
2009 -
2008 -
2007 -
2006 -
2005 -
2004 -
Access this data via the Eulerpool API

Probi Stock analysis

What does Probi do? Probi AB is a Swedish company that specializes in the development and production of probiotic products. Founded in 1991 as a spin-off from Lund Institute of Technology, Probi is now represented in Sweden, the USA, and India with approximately 200 employees. The business model of Probi is based on research and development of probiotic bacterial cultures, as well as marketing probiotic products developed in collaboration with customers and partners. The company's business divisions are divided into probiotic products and research and development. Probiotic products: Probi produces a wide range of probiotic products, including dietary supplements, functional foods, animal feed, and medical devices. These products contain live microorganisms intended to support gut health and strengthen the immune system. Probi works closely with customers and partners to develop tailored solutions. Research and development: An important part of Probi's business is the research and development of probiotic bacterial cultures. Research findings serve as the basis for new products and applications. Probi has its own research department equipped with state-of-the-art laboratory technologies. In addition, Probi collaborates closely with partners from the academic and industrial sectors to explore new technologies and applications. Probi's history originally began in the 1980s at Lund Institute of Technology in Sweden, where the foundation for the development of probiotics was laid. In 1991, Probi was established as a spin-off from the institute, initially focusing on research and development of probiotic bacterial cultures. Over the following years, the company expanded internationally and developed more and more products and applications. Today, Probi is a leading global provider of probiotic products and solutions. Probi's products include probiotic capsules and tablets, probiotic yogurts, beverages, and dietary supplements. These products are intended to stabilize gut flora and strengthen the immune system. Additionally, Probi offers animal feed with probiotic bacterial cultures to promote the health of livestock. An important aspect of Probi is its collaboration with partners and customers. Through these partnerships, innovative products and solutions are developed to meet the needs of customers. Probi works closely with the food industry, healthcare sector, and animal feed industry. The future of Probi looks promising. The company aims to continue developing innovative products and solutions to promote the health of humans and animals. A strong growth strategy will also be pursued to further expand international presence. Probi is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Probi stock

EV/EBIT (Enterprise Value to EBIT) of Probi is 350.28 in 2026.

Access this data via the Eulerpool API

Valuation — Probi

All Key Metrics — Probi